Compared to T-ALL or B-ALL, super-enhancers associated with MPO were observed to be AML specific, while super-enhancers associated with ZFP36L2 were common to all three hematological diseases (AML, T-ALL, and B-ALL) (Supplementary Figs. 1 and 2). This evidence concerns the gene MPO and acute myeloid leukemia.